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Summary
African American (AA) women have poorer breast cancer survival compared to Caucasian American (CA) women.
The purpose of this analysis was to determine whether socioeconomic status (SES) and treatment differences
influence racial differences in breast cancer survival. The study population included 9,321 women (82% CA, 18%
AA) diagnosed with local (63%) or regional (37%) stage disease between 1988 and 1992, identified through the
Metropolitan Detroit SEER registry. Data on SES were obtained through linkage with the 1990 Census of Popu-
lation and Housing Summary Tape and cases were geocoded to census block groups. Pathology, treatment and
survival data were obtained through SEER. Cox proportional hazards models were used to compare survival for AA
versus CA women after adjusting for age, SES, tumor size, number of involved lymph nodes, and treatment.
AA women were more likely to live in a geographic area classified as working poor than were CA women (p<0.001).
AA women were less likely to have lumpectomy and radiation and more likely to have mastectomy with radiation
(p<0.001). After multivariable adjusted analysis, there were no significant racial differences in survival among
women with local stage disease, although AAwomen with regional stage disease had persistent but attenuated poorer
survival compared to CA women. After adjusting for known clinical and SES predictors of survival, AA and CA
women who are diagnosed with local disease demonstrate similar overall and breast cancer-specific survival, while
race continues to have an independent effect among women presenting at a later stage of disease.
Introduction
Although breast cancer (BC) incidence rates are higher
among Caucasian American (CA) women than African
American (AA) women in the U.S. [1], mortality from
breast cancer is higher among AA women [2]. A number
of population-based studies using Surveillance Epide-
miology and End Results (SEER) registry data [3–13] as
well as studies of populations from hospitals and health
care systems [14–19], have shown worse prognostic
features and lower survival rates for AA and other
ethnic minority women with BC compared with CA
women. At least some of the reported racial differences
in survival could be accounted for by either socioeco-
nomic differences [3,5,12,13,18–21] and or differences in
access to medical care or poor quality care
[7–9,11,15,22]. In a recently published analysis of AA
and CA female breast cancer patients treated at a single
large comprehensive cancer center in Detroit, no mea-
surable racial differences in treatments were found, and
multivariate adjusted analysis revealed no racial differ-
ences in disease free or overall survival [14]. The results
of this latter study suggest that equal access to treatment
results in equal outcomes.
We previously reported on racial differences in breast
cancer survival in the Detroit Metropolitan area [3,22]
showing a significant interaction between age at diag-
nosis and race. The current report updates our previous
work by nearly doubling the period of follow-up, taking
into account differences in cancer directed treatment and
using a more refined measure of socioeconomic status
(SES) [23]. We confined the current analysis to women
diagnosed with either local or regional stage disease
since in this and previous analyses [3] we found no racial




The study population consisted of women diagnosed
with a first primary invasive breast cancer (International
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Classification of Diseases for Oncology ICD-O codes C
50.0 to C 50.9) [24] from 1988 through 1992, identified
through the population-based Metropolitan Detroit
Cancer Surveillance System (MDCSS). The MDCSS is
one of 7 founding members of the National Cancer
Institute’s Surveillance, Epidemiology, and End Results
(SEER) program, which was initiated in 1973 [2]. For
the current analysis we included women with either local
or regional stage disease as defined by the SEER pro-
gram. Localized stage includes invasive carcinoma confined
to the breast. Regional stage includes invasive carcinoma
spread beyond the breast, either by direct extension or to
regional lymph nodes [25]. All women in the analysis were
residents of the tri-county Detroit metropolitan area
(Wayne, Oakland and Macomb counties) at the time of
diagnosis. Women whose only documentation of BC was
by death certificate were not included.
From 1988 to 1992 there were 10,314 incident cases
of female invasive breast cancer diagnosed in the Detroit
metropolitan area. We excluded 717 (6.95%) women
from our analysis with distant (metastatic) disease at
diagnosis because survival was similarly poor for both
racial groups in our preliminary analyses. There were
an additional 276 (2.67%) women excluded for whom
tumor size could not be classified because there was
either no mass identified, only microscopic tumor foci
were noted, Paget’s disease or inflammatory breast
cancer were diagnosed. The population for analysis
consisted of 9321 women: 7641 (82.0%) were classified
in the SEER registry as CA and 1680 (18.0%) were
classified as AA.
Measurement of variables
Medical and demographic data were obtained by the
MDCSS on incident BC cases from all area facilities
that provide medical care including hospitals, radiation
therapy facilities, and private laboratories. Demo-
graphic data collected included age at diagnosis and race
(AA or CA). Using address at diagnosis, the SES Group
variable was developed through a geo-coding process
that first assigned a census block-group number, as
previously described [26]. Aggregate socioeconomic data
specific to census block-groups were obtained from the
1990 U.S. Census of Population and Housing Summary
Tape File 3A [27]. The variables and codes used to
calculate the SES Group for each census block were
occupation (P078), poverty status in 1989 (P119), edu-
cational attainment (P057), and age (P013).
The U.S. Census Bureau uses 13 occupational cate-
gories of which five are defined as ‘‘professional’’
occupations and the remaining 8 are identified as
‘‘working class’’ occupations. Working class block-
groups were defined as those areas in which 66% or
more of employed persons in that particular block-
group reported a working class occupation, such as
administrative support or laborer. Professional block-
groups were defined as those areas where 34% or more
of employed persons had supervisory or executive
positions. Poor block-groups had 20% or more of the
population below poverty level, defined as an income of
$12,674 for family of four in 1990. Educational status
was used to classify block-groups as either educated, in
which 75% or more of persons age 25 years and older
had completed at least a high school education, or
undereducated block groups.
The SES Groups for this analysis were computed for
each woman according to the method of Krieger et al.
[28]. Women were initially assigned to one of eight SES
Groups which included: (1) Working, Poor, Underedu-
cated, (2) Working, Poor, Educated, (3) Working,
Non-poor, Undereducated, (4) Working, Non-poor,
Educated, (5) Professional, Poor, Undereducated, (6)
Professional, Poor, Educated, (7) Professional, Non-
poor, Undereducated, and (8) Professional, Non-poor,
Educated. Due to small numbers of cases in some
groups, we collapsed cases into four mutually exclusive
SES categories: (1) Working, Poor (WP); (2) Working,
Non-poor, Undereducated (WNP-UE); (3) Working,
Non-poor, Educated (WNP-E); and (4) Professional (P).
Clinical data included registry stage (as defined
above), tumor size, number of involved axillary lymph
nodes, histological grade, and hormone receptor status
(estrogen receptor status (ER) and/or progesterone
receptor (PR)). Information was collected on breast
cancer directed therapy from the SEER ‘‘first course of
treatment’’ variable. Treatment categories included
lumpectomy or mastectomy with or without radiation
therapy. Information on the administration of chemo-
or hormonal therapy was not included in this analysis
because these treatments are often administered outside
the facilities where SEER data are collected, and are
thereby known to be incomplete.
Follow-up of all patients through June 2002 occurred
by record linkage to hospital tumor registries, physician
contacts, hospices, voting records, driver’s license
records, death certificates and review of obituaries [2].
Overall survival (measured in months) was calculated as
the interval between date of diagnosis and date of last
follow-up (censored observations) or death from any
cause. We analyzed both overall survival and breast
cancer specific survival. By the end of the study period,
3822 deaths had occurred, with 3001 deaths among CA
women (39.3% of all CA women) and 821 deaths among
AA women (48.9% of all AA women). Breast cancer
was listed on death certificate as the underlying cause
of death for 1,812 of the women who had died. This
included 1359 deaths from breast cancer among CA
women (17.8% of all CA women) and 453 BC deaths
among AA women (27% of all AA women).
Design and analysis
Mantel-Haenszel chi-square statistics were used to
compare the distributions of demographic and clinical
characteristics in the two racial groups studied.
(Table 1) [29]. Cox proportional hazards regression was
used to estimate the hazard ratio (HR, 95% CI) of death
150 MS Simon et al.
from any cause, as well as breast cancer specific deaths,
in AA women compared to CA women while controlling
for appropriate covariates [30]. Survival analyses were
stratified by SEER registry stage (local or regional stage)
of disease. Independent variables used in the multivari-
able Cox model included race (AA vs. CA), age at
diagnosis (£ 50 vs. >50), SES group (WP, WNP-UE,
WNP-E, P) tumor size (£ 2 cm, 2.1–5 cm, >5 cm) lymph
node involvement (0, 1–3, 4–9, ‡10) and cancer-directed
treatment (lumpectomy, lumpectomy + radiation,
mastectomy, mastectomy + radiation). Tumor grade
and hormone receptor status were not included in the
multivariable model because of the large proportion of
missing data (over 50%) for these variables. Potential
interactions between race and other independent vari-
ables were assessed and the statistical significance of
Table 1. Distribution of demographic and clinical characteristics by race among women with invasive breast cancer diagnosed in the Detroit
Metropolitan area (1988–1992)a
Characteristic AA CA p-value
n % n %
Age (years)
£ 50 562 33.45 1821 23.84 <0.001
>50 1118 66.55 5820 76.16
SES groupb
WP 1045 62.20 595 7.79 <0.001
WNP-UE 213 12.68 1827 23.91
WNP-E 99 5.89 1705 22.31
P 321 19.11 3510 45.94
Missing 2 0.12 4 0.05
Tumor size
£ 2 cm 718 42.74 4372 57.21 <0.001
2.1–5 cm 664 39.52 2279 29.82
5.1–10 cm 135 8.04 323 4.23
>10 cm 16 0.95 29 0.38
Missing 147 8.75 638 8.36
Lymph node involvement
0 784 46.67 4281 56.02 <0.001
1–3 349 20.77 1412 18.48
4–9 169 10.06 616 8.06
‡ 10 83 4.94 347 4.54
Missing 295 17.56 985 12.90
Treatment
Lumpectomy 190 11.31 812 10.63 <0.001
Lumpectomy + Radiation 295 17.56 1660 21.72
Mastectomy 1030 61.31 4705 61.58
Mastectomy + Radiation 131 7.8 369 4.83
Missing 34 2.02 95 1.24
Grade
Well Differentiated 58 3.45 333 4.36 <0.001
Moderately Differentiated 267 15.89 1126 14.73
Poorly Differentiated 437 26.01 1231 16.11
Undifferentiated 42 2.5 113 1.48
Missing 876 52.14 4838 63.32
ER
Positive 469 27.92 2710 35.46 <0.001
Negative 284 16.90 698 9.13
Missing 927 55.18 4233 55.4
PR
Positive 413 24.58 2322 30.38 <0.001
Negative 339 20.18 1048 13.71
Missing 928 55.24 4271 55.90
aIncludes only women with localized and regional stage disease according to the SEER stage criteria.
bWP-working poor; WNP-UE-working, non-poor, undereducated; WNP-E-working, non-poor, educated; P-professional.
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interaction terms was evaluated using likelihood ratio
tests.
Results
Demographic and clinical characteristics of the study
cohort stratified by race are listed in Table 1. The mean
age at diagnosis was 61 years (range 17–104) and the
median period of follow-up was 97 months (maximum
154). There were statistically significant differences
between AA and CA for all of the independent variables
listed in the table. AA women were more likely than CA
to be younger at diagnosis with 33% of AA women
diagnosed at age 50 or younger compared to 24% of CA
women (p<0.001). AA women were more likely to re-
side in a census area that had a higher proportion of
individuals categorized as WP and a lower proportion
categorized as P. At the time of diagnosis, 62% of AA
women resided in a WP census block while only 19% of
AA patients resided in P census block. In contrast, 8%
of CA women resided in a WP block, and 46% resided
in a P block (p<0.001).
AA women were also more likely than CA women to
have more advanced stage tumors at diagnosis. AA
women were more likely to present with larger diameter
tumors (almost twice as many AA vs. CA had tumors
greater than 5 cm in greatest diameter, p<0.001) and
were also more likely to present with axillary lymph
nodes that were involved with cancer (36% of AA
compared with 31% of CA, p<0.001). A greater pro-
portion of AA women had poorly differentiated tumors
(26% vs. 16% p<0.001), and a greater proportion of
tumors among AA women were either ER negative
(17% vs. 9% p<0.001) or PR negative (20% vs. 14%
p<0.001).
In regards to treatment, AA women were more likely
than CA women to have had a mastectomy (69% vs.
66% p<0.001) and less likely to have had lumpectomy
(29% vs. 32% p<0.001) with the greatest percentage
difference by race seen among women who received both
lumpectomy and radiation therapy (18% for AA vs.
22% for CA p<0.001).
The results of multivariable models of racial differ-
ences in overall survival are stratified by SEER registry
stage (Table 2). Each model provides the unadjusted
hazard ration (HR) for race and the adjusted HR con-
trolling for age, SES group, tumor size, axillary lymph
node involvement and treatment. By definition, whether
or not axillary lymph nodes were involved was not
applicable for patients with local stage disease. While
the unadjusted HR (95% CI) of death for AA compared
Table 2. Hazards of the risk of overall death among AA and CA women with local and regional disease
Characteristic Local (n=5890) HR (95% CI) Regional (n=3431) HR (95% CI)
Unadjusted
Race (Black vs. White) 1.28 (1.15–1.44) 1.45 (1.30–1.61)
Multivariable adjusted
Race (Black vs. White) 1.07 (0.90–1.27) 1.27 (1.10–1.46)
Age (years)
£ 50 1.00 1.00
>50 2.35 (2.00–2.77) 1.58 (1.41–1.77)
SES groupa
WP 1.34 (1.13–1.60) 1.24 (1.06–1.45)
WNP-UE 1.18 (1.03–1.35) 1.20 (1.05–1.36)
WNP-E 0.99 (0.85–1.15) 1.02 (0.88–1.17)
P 1.00 1.00
Tumor size
£ 2 cm 1.00 1.00
2.1–5 cm 1.51 (1.34–1.70) 1.59 (1.42–1.77)








Lumpectomy+Radiation 0.81 (0.62–1.05) 0.76 (0.57–1.02)
Mastectomy 1.08 (0.85–1.37) 0.89 (0.68–1.15)
Mastectomy+Radiation 1.24 (0.8–1.91) 1.15 (0.87–1.53)
aWP-working poor; WNP-UE-working, non-poor, undereducated; WNP-E-working, non-poor, educated; P-professional.
152 MS Simon et al.
to CA (Table 2) was 1.28 (1.15–1.44) for local, and 1.45
(1.30–1.61) for regional stage, the multivariable adjusted
HR (95% CI) of death for AA vs. CA was not signifi-
cantly different for women with local stage breast cancer
1.07 (0.90–1.27), but was significantly worse for AA vs.
CA among women with regional stage disease 1.27
(1.10–1.46). Older women had a greater risk of death
than younger women with a HR (95% CI) of 2.35
(2.0–2.77) and 1.58 (1.41–1.77) for local and regional
stage disease, respectively. Also women who lived in a
census block group ranked as WP or WNP-UE had a
higher risk of death, compared to women who resided in
a P census block group (HR (95% CI) 1.34 (1.13–1.6)
and 1.18 (1.03–1.35) respectively for local stage disease,
and 1.24 (1.06–1.45) and 1.20 (1.05–1.36) respectively
for regional stage disease). Women diagnosed with lar-
ger tumors or those with involved axillary lymph nodes
(for regional stage only) had worse survival as well.
There were no significant differences in overall survival
by treatment group for either local or regional stage
disease.
The results of multivariable models of racial differ-
ences in breast cancer specific survival stratified by
SEER registry stage are shown in Table 3. Multivariable
adjustment resulted in non-significant differences in
survival for AA vs. CA women with local stage disease
HR (95% CI) 1.03 (0.77–1.37). However, among women
with regional stage disease, AA women continued to
have significantly worse breast cancer specific survival
compared to CA (HR (95% CI) 1.40 (1.18–1.66). In
these models, age was not a significant predictor of
survival, and while women who resided in a census block
group categorized as either WP, or WP-UE had worse
survival than women living in a P census block group,
these differences were not statistically significant. Tumor
size and lymph node status were again significant pre-
dictors of survival. There were no overall significant
differences by treatment for regional stage disease.
However, women treated with mastectomy and radia-
tion therapy for local stage disease had worse outcome
compared to women who had lumpectomy alone (HR
2.66, 95% CI 1.36–5.18).
Discussion
The disproportionately higher mortality rates experi-
enced by AA women compared to CA women with
breast cancer [2,31], accompanied by lower incidence
rates except for women in the youngest age groups [1], is
a matter of significant public health concern. The degree
and extent to which differences in incidence and survival
can be explained by inherent racial differences in tumor
biology, and/or by factors associated with access to care,
Table 3. Hazards of the risk of breast cancer-specific death among AA and CA women with local and regional disease
Characteristic Local (n=5890) HR (95% CI) Regional (n=3431) HR (95% CI)
Unadjusted
Race (Black vs. White) 1.53 (1.26–1.87) 1.61 (1.41–1.82)
Multivariable adjusted
Race (Black vs. White) 1.03 (0.77–1.37) 1.40 (1.18–1.66)
Age (years)
£ 50 1.00 1.00
>50 0.98 (0.79–1.21) 1.06 (0.93–1.21)
SES groupa
WP 1.32 (0.97–1.80) 1.16 (0.96–1.42)
WNP-UE 1.24 (0.97–1.58) 1.20 (1.03–1.41)
WNP-E 1.00 (0.78–1.31) 1.04 (0.87–1.24)
P 1.00 1.00
Tumor size
£ 2 cm 1.00 1.00
2.1–5 cm 2.49 (2.04–3.04) 1.73 (1.50–1.98)








Lumpectomy+Radiation 1.19 (0.71–2.00) 0.90 (0.62–1.31)
Mastectomy 1.32 (0.81–2.16) 0.96 (0.69–1.34)
Mastectomy+Radiation 2.66 (1.36–5.18) 1.38 (0.97–1.98)
aWP-working poor; WNP-UE-working, non-poor, undereducated; WNP-E-working, non-poor, educated; P-professional.
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is an issue that is currently being debated [31,32]. The
result of this survival analysis of AA and CA women
with breast cancer from the Detroit metropolitan area
represents an update of an earlier analysis in which we
noted an interaction between race and age, with AA
women who were less than age 50 at diagnosis having
worse survival experiences compared to CA women than
their older counterparts.
In this report, we extended the period of follow-up
from a prior maximum of 78 months [3], to 154 months,
almost double the prior time period. We assessed both
overall and disease specific survival, and also looked at
the effect of SES on survival by incorporating a more
refined measure of SES than we had used previously [3].
The current analyses show that AA women were more
likely than CA women to reside in economically disad-
vantaged census areas, and more likely to present with
more advanced breast cancer at the time of diagnosis. In
addition, AA women were less likely to have had lump-
ectomy alone, or lumpectomy and radiation, and were
more likely to have had mastectomy than CA women.
Unadjusted survival analysis showed worse overall and
disease specific survival for AA women, although after
adjustment for common prognostic characteristics, SES,
and treatment, racial differences in both overall and dis-
ease specific survival were no longer apparent for women
diagnosed with local stage disease. Differences in survival
by race for women with regional stage disease persisted,
but were attenuated in the multivariable models.
Several previous reports have looked at the effects
of SES and access to care on racial differences in
breast cancer survival [3,5,7–9,11–13,15,18–22]. Using
SEER data for the years 1992 through 1998, Li et al
[11] showed that AA and other ethnic minority women
were less likely than CA women to receive a first
course of surgical and radiation treatment that met
current standards of care. In another SEER based
analysis, AA women were similarly shown to be less
likely to receive breast radiotherapy [8]. In two prior
reports of treatment utilization using the Detroit
SEER registry, we found that AA women were less
likely to undergo lumpectomy and radiation therapy
[33], or lumpectomy alone [22] which is consistent with
our current results. In the current report AA women
were more likely to need radiation following mastec-
tomy which is likely indicative of more advanced dis-
ease. It is of interest that when assessed on a
population basis, there appears to be disparity in
treatment utilization, though a recent report of treat-
ment utilization at a single NCI-designated compre-
hensive cancer center in Detroit revealed no racial
differences in the utilization of surgery, radiation
therapy, chemotherapy or hormonal therapy for breast
cancer [14]. These latter results imply that when
women are exposed to state-of-the-art treatment that
racial differences in utilization of treatment are no
longer evident.
Other investigators have shown that access to care
and other sociodemographic factors account at times for
a large component of the noted survival differences
between AA and CA women with breast cancer. Chu
et al. found racial differences in survival for younger
women compared with women aged 65 and older, con-
cluding that access to Medicare (which covered treat-
ment costs) allowed for better survival among older
women with breast cancer [9]. Adjustment for either
prior mammography [15], treatment [8] or SES
[3,5,13,18,20,21] has accounted for a significant compo-
nent of racial/ethnic differences in breast cancer survival
in other studies. Because SES is known to be a significant
predictor of stage at diagnosis [26], and stage at diagnosis
is a strong predictor of survival, it is not surprising that
we found an attenuation of racial differences after
adjustment for SES. As suggested by others, our results
indicate that known prognostic and predictive factors as
well as SES account for at least some of the racial dif-
ferences in survival seen among women with breast
cancer in the Detroit metropolitan area.
The strengths of analyzing SEER registry data derive
from the population-based data, the large number of
cases, and the long period of follow-up. Weaknesses
include missing data for some clinical variables and the
fact that socioeconomic status, as derived from grouped
census data, represents only a surrogate rather than an
actual measure of individual socioeconomic status. On
the other hand, some have argued that neighborhood
SES also functions as a predictor of access to care [23].
Further research is needed to better quantify SES and to
determine interventions at the community level which
might have an impact on racial and SES differences in
cancer mortality.
This report adds to the growing volume of data
documenting racial inequity in cancer diagnosis, treat-
ment and survival. While debate continues as to the
relative degree in which biologic differences vs. access to
care impact racial differences in survival, our results as
well as others highlight the effect of SES on breast
cancer survival. It is incumbent on the health care pro-
fession to help find solutions to inequities in access to
care in our society. Mammographic screening should be
accessible to all eligible women in order to eliminate the
well described gap in stage at breast cancer presentation
for AA and CA women.
Acknowledgements
This research was supported in part by SEER contract
NIH:NCI N01-PC-35154.
References
1. Simon MS, Korczak JF, Yee CL, Daling JR, Malone KE, Bern-
stein L, et al.: Racial differences in the familial aggregation of
breast cancer and other female cancers. Breast Cancer Res Treat
89: 227–235, 2005
2. Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA,
et al.: Annual report to the nation on the status of cancer, 1975–
154 MS Simon et al.
2000, featuring the uses of surveillance data for cancer prevention
and control. J Natl Cancer Inst 95(17): 1276–1299, 2003
3. Simon MS, Severson RK: Racial differences in survival of female
breast cancer in the Detroit metropolitan area. Cancer 77(2): 308–
314, 1996
4. Edwards MJ, Gamel JW, Vaughan WP, Wrightson WR: Infil-
trating ductal carcinoma of the breast: the survival impact of race.
J Clin Oncol 16(8): 2693–2699, 1998
5. O’Malley CD, Le GM, Glaser SL, Shema SJ, West DW: Socio-
economic status and breast carcinoma survival in four racial/eth-
nic groups: a population-based study. Cancer 97(5): 1303–1311,
2003
6. Clegg LX, Li FP, Hankey BF, Chu K, Edwards BK: Cancer
survival among US whites and minorities: a SEER (Surveillance,
Epidemiology, and End Results) Program population-based study.
Arch Intern Med 162(17): 1985–1993, 2002
7. Shavers VL, Harlan LC, Stevens JL: Racial/ethnic variation in
clinical presentation, treatment, and survival among breast cancer
patients under age 35. Cancer 97(1): 134–147, 2003
8. Joslyn SA: Racial differences in treatment and survival from early-
stage breast carcinoma. Cancer 95(8): 1759–1766, 2002
9. Chu KC, Lamar CA, Freeman HP: Racial disparities in breast
carcinoma survival rates: seperating factors that affect diagnosis
from factors that affect treatment. Cancer 97(11): 2853–2860, 2003
10. Joslyn SA: Hormone receptors in breast cancer: racial differences
in distribution and survival. Breast Cancer Res Treat 73(1): 45–59,
2002
11. Li CI, Malone KE, Daling JR: Differences in breast cancer stage,
treatment, and survival by race and ethnicity. Arch Intern Med
163(1): 49–56, 2003
12. Grann V, Troxel AB, Zojwalla N, Hershman D, Glied SA, Jac-
obson JS: Regional and racial disparities in breast cancer-specific
mortality. Soc Sci Med: Epud ahead of print, 2005
13. Delgado DJ, Lin WY, Coffey M: The role of Hispanic race/eth-
nicity and poverty in breast cancer survival. P R Health Sci J 14(2):
103–116, 1995
14. Du W, Simon MS: Racial disparities in treatment and survival of
women with stage I-III breast cancer at a large academic medical
center in Metropolitan Detroit. Breast Cancer Res Treat, 2005
15. Wojcik BE, Spinks MK, Stein CR: Effects of screening mam-
mography on the comparative survival rates of African American,
white, and Hispanic beneficiaries of a comprehensive health care
system. Breast J 9(3): 175–183, 2003
16. Jatoi I, Becher H, Leake CR: Widening disparity in survival
between white and African-American patients with breast carci-
noma treated in the US Department of Defense Healthcare system.
Cancer 98(5): 894–899, 2003
17. Mancino AT, Rubio IT, Henry-Tillman R, Smith LF, Landes
R, Spencer HJ, et al.: Racial differences in breast cancer sur-
vival: the effect of residual disease. J Surg Res 100(2): 161–165,
2001
18. Yood MU, Johnson CC, Blount A, Abrams J, Wolman E,
McCarthy BD, et al.: Race and differences in breast cancer sur-
vival in a managed care population. J Natl Cancer Inst 91(17):
1487–1491, 1999
19. Ansell D, Whitman S, Lipton R, Cooper R: Race, income, and
survival from breast cancer at two public hospitals. Cancer 72(10):
2974–2978, 1993
20. Bradley CJ, Given CW, Roberts C: Race socioeconomic status,
and breast cancer treatment and survival. J Natl Cancer Inst 94(7):
490–496, 2002
21. Gordon NH, Crowe JP, Brumberg DJ, Berger NA: Socioeconomic
factors and race in breast cancer recurrence and survival. Am J
Epidemiol 135(6): 609–618, 1992
22. Simon MS, Severson RK: Racial differences in breast cancer sur-
vival: the interaction of socioeconomic status and tumor biology.
Am J Obstet Gynecol 176(6): S233–S239, 1997
23. Diez-Roux AV, Kiefe CI, Jacobs DR, Jr., Haan M, Jackson SA,
Nieto FJ, et al : Area characteristics and individual-level socio-
economic position indicators in three population-based epidemi-
ologic studies. Ann Epidemiol 11(6): 395–405, 2001
24. International classification of diseases for oncology. 2nd ed. World
Health Organization, Geneva, 1990
25. Henson DE, Ries L, Shambaugh EM: Survival results depend on
the staging system. Semin Surg Oncol 8(2): 57–61, 1992
26. Schwartz KL, Crossley-May H, Vigneau FD, Brown K, Banerjee
M: Race, socioeconomic status and stage at diagnosis for five
common malignancies. Cancer Causes Control 14(8): 761–766,
2003
27. US Census Bureau. Census of Population and Housing Summary
Tape File 3 Technical Documentation. 1991. US Census Bureau,
Washington DC, 1990
28. Krieger N, Quesenberry C, Jr., Peng T, Horn-Ross P, Stewart S,
Brown S, et al : Social class, race/ethnicity, and incidence of
breast, cervix, colon, lung, and prostate cancer among Asian,
Black, Hispanic, and White residents of the San Francisco Bay
Area, 1988–92 (United States). Cancer Causes Control 10(6): 525–
537, 1999
29. Neter J, Wasserman W, Kutner M: Applied linear statistical
models: regression, analysis of variance and experimental design.
2nd ed. Richard D. Irwin, Inc, Homewood, IL, 1985
30. Cox DR, Oakes DO: Analysis of survival data. Chapman and
Hall, London, 1984
31. Newman LA, Mason J, Cote D, Vin Y, Carolin K, Bouwman D,
et al : African-American ethnicity, socioeconomic status, and
breast cancer survival: a meta-analysis of 14 studies involving over
10,000 African-American and 40,000 White American patients
with carcinoma of the breast. Cancer 94(11): 2844–2854, 2002
32. Shavers VL, Brown ML: Racial and ethnic disparities in the
receipt of cancer treatment. J Natl Cancer Inst 94(5): 334–357,
2002
33. Chuba PJ, Simon MS: Trends in primary surgical and radiation
therapy for localized breast cancer in the Detroit Metropolitan
area 1973–1992. Int J Radiat Oncol Biol Phys 38(1): 103–107, 1997
Address for offprints and correspondence: Michael S. Simon, Barbara
Ann Karmanos Cancer Institute, 4100 John R, 4221 HWCRC Detroit,
MI, USA; Tel.: +1-313-576-8727; Fax: +1-313-576-8764; E-mail:
Simonm@karmanos.org
Racial differences in breast cancer survival 155
